Cost-effectiveness of denosumab (D) versus zoledronic acid (Z) for skeletal-related event (SRE) reduction in bone-metastatic prostate cancer (mPC) in the United Kingdom.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Marc Botteman, John A. Carter, Peter Fishman, David Chandiwana, Manjinder Bains, Sonya J. Snedecor
Institutions: Pharmerit (United States), Novartis (United Kingdom)
Language: English
Topic: Bone health and treatments
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2792135414